# Nemtabrutinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nemtabrutinib

> The next catalyst for nemtabrutinib, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, May to Aug 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | nemtabrutinib |
| Codes | ARQ-531, MK-1026 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Hematologic Malignancies](https://sec-api.dev/indications/hematologic-malignancies), [Chronic Lymphocytic Leukemia](https://sec-api.dev/indications/chronic-lymphocytic-leukemia) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05624554

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05624554

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04728893 (Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04728893

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04728893 (Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04728893

## Same indication

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [APG2575](https://sec-api.dev/pdufa/apg2575) (AAPG)
- [Emavusertib](https://sec-api.dev/pdufa/emavusertib) (CRIS)
- [Imbruvica (ibrutinib)](https://sec-api.dev/pdufa/ibrutinib) (ABBV)
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib) (LLY)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg) (ONC)
- [MINJUVI (tafasitamab)](https://sec-api.dev/pdufa/tafasitamab) (INCY)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nemtabrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nemtabrutinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nemtabrutinib

```bibtex
@misc{secapidev_pdufa_nemtabrutinib_20261116,
  title        = {Nemtabrutinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nemtabrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nemtabrutinib_20261116","title":"Nemtabrutinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nemtabrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
